{
    "nctId": "NCT05274451",
    "briefTitle": "A Study to Investigate LYL797 in Adults with Solid Tumors",
    "officialTitle": "A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed And/or Refractory Solid-Tumor Malignancies",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Evaluate incidence of dose-limiting toxicities (DLTs)",
    "eligibilityCriteria": "IInclusion Criteria:\n\n* \u2265 18 years of age at time of informed consent\n* Confirmation of ROR1 expression from a pretreatment tumor sample\n* Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable\n* Platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer.\n* Endometrial cancer.\n* Measurable disease including a target lesion and an additional lesion for biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate organ and marrow function\n* Women of childbearing potential must have a negative pregnancy test at screening\n* All participants must agree to practice highly effective methods of contraception\n\nExclusion Criteria:\n\n* Prior treatment with any adoptive T-cell therapy or other anti-ROR1 therapy\n* Prior solid organ transplantation\n* Active, untreated brain metastasis or leptomeningeal disease; however, stable, treated brain metastases are allowed\n* Untreated or active infection at the time of screening or leukapheresis\n* HIV-positive, HTLV-1-positive, active acute HAV, acute or chronic HBV or HCV, or active tuberculosis\n* Impaired cardiac function or clinically significant cardiac disease\n* Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures (once monthly or more frequent), or lymphangitis carcinomatosis\n* History of interstitial pneumonitis or pulmonary fibrosis.\n* Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis\n* Pregnant or lactating/nursing women",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}